The 30th Annual Meeting of
Japanese Association for Molecular Target Therapy of Cancer

Chairperson Hidetoshi Tahara
Professor, Department of Cellular and Molecular Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University

It is my great honor to serve as the chairperson of the 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer.I am Hidetoshi Tahara from the Graduate School of Biomedical and Health Sciences, Hiroshima University. It is a profound privilege to be appointed as a chairperson of this Association, which leads the drug discovery and practical application of cancer molecular targeted therapy, especially at the milestone of its 30th annual meeting.
I extend my sincere gratitude to all.
The 30th Annual Meeting of Japanese Association for Molecular Target Therapy of Cancer will be held for three days, from Tuesday, June 30th to Thursday, July 2nd, 2026, at the Grand Prince Hotel Hiroshima, which offers views of the islands of the Seto Inland Sea and also served as the venue for the G7 Summit. The theme for this year's meeting is Pioneering the Future through the Drug Discovery Ecosystem! ~Challenges in Innovating and Practicalizing Cancer Treatment~".
This academic meeting aims to provide a platform for active discussions across a wide range of fields, from basic research in drug discovery to cutting-edge applied research. We have also prepared numerous programs to encourage active participation from startups, young researchers, and international researchers, including the "Scientists' Diversity Symposium" and the "Industry-Academia Collaboration Symposium." Specifically, we have implemented a mechanism for one-on-one meetings between researchers and pharmaceutical companies or startup supporters to accelerate the practical application of drug discovery in Japan. Our goal is to increase the likelihood of matching researchers facing challenges in drug practical application with pharmaceutical companies seeking academic seeds.
Furthermore, in collaboration with JARI (the Japanese Association for RNAi), we will hold related events immediately following the main academic meeting, from Thursday, July 2nd to Saturday, July 4th, 2026. These events will feature deeper discussions on the challenges of drug practical application and the drug discovery ecosystem. Additionally, a pitch event will be jointly organized with the Japanese Association for Molecular Target Therapy of Cancer, featuring researchers planning drug discovery startups and those who have already established their own companies.
Given that approximately 80% of drug practical application is currently driven by startups, our association believes it is crucial to collectively consider the challenges in drug practical application and find solutions together with all participants.
Amidst ongoing global threats to peace, Hiroshima plays a vital role as a symbol of peace. In holding this meeting in Hiroshima, we will also strive to disseminate cancer research that champions the pursuit of peace.
We sincerely look forward to engaging in meaningful scientific discussions with all of you.
We eagerly await your participation.